LACTOLOGY FOUNDATION

Prucalopride (A06AX05) is a selective 5‑HT4 receptor agonist with prokinetic activity used for chronic idiopathic constipation, and available data indicate that it appears in breast milk at low levels, allowing cautious use in breastfeeding with infant monitoring after failure of first‑line laxatives.atcddd.fhi+9

Pharmacotherapeutic group and mechanism

Prucalopride is classified in ATC subgroup A06AX “Other drugs for constipation” under code A06AX05.atcddd.fhi+4
It is a dihydrobenzofurancarboxamide derivative and highly selective serotonin 5‑HT4 receptor agonist that enhances colonic motility by stimulating peristaltic activity and colonic mass movements, thereby increasing bowel frequency in patients with chronic constipation.kegg+3

Indications, dosage and administration

Prucalopride is indicated for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief, and in some jurisdictions it is approved for chronic idiopathic constipation (CIC) under brand names such as Resolor and Motegrity.mothertobaby+3
The WHO ATC/DDD Index lists prucalopride with a defined daily dose of 2 mg oral, reflecting standard adult therapy.atcddd.fhi

Typical dosing:

• Adults: 2 mg once daily; some patients, particularly older adults or those with severe renal impairment, may start at 1 mg once daily.medicines+1
• Use is reserved for patients in whom lifestyle measures and conventional bulk, osmotic or stimulant laxatives have been tried and found insufficient.sps+3

General toxicological profile

The most common adverse effects of prucalopride include headache, abdominal pain, nausea and diarrhea, particularly during the first days of therapy; these are usually mild to moderate and tend to resolve with continued treatment.pharmindex-online+2
Because prucalopride is a prokinetic agent, diarrhea can be more pronounced in some patients; persistent or severe diarrhea may require dose reduction or discontinuation.

Cardiovascular safety has been closely evaluated: unlike some earlier 5‑HT4 agonists, prucalopride has not shown clinically relevant QT prolongation or increased rates of major adverse cardiovascular events at therapeutic doses in large trials. Other adverse effects include dizziness, fatigue and, rarely, rectal bleeding or vomiting. Prucalopride is contraindicated in patients with intestinal perforation or obstruction, severe inflammatory bowel disease, or toxic megacolon, and should be used with caution in severe renal impairment.kegg+3

Lactation‑toxicology considerations

Specialist breastfeeding guidance notes that prucalopride is excreted into breast milk at small levels and “can be used with caution whilst breastfeeding,” although other laxatives are generally preferred as first‑line options.sps+1
A pharmacokinetic study in healthy lactating women receiving prucalopride 2 mg once daily for 4 days found a milk‑to‑plasma AUC ratio of approximately 2.65:1, with an estimated infant dose of 1.74 mcg/kg/day—about 6% of the maternal weight‑adjusted dose. This exposure is below the commonly used 10% threshold of concern for many drugs and suggests that infant systemic exposure is minimal.ncbi.nlm.nih+1

Regulatory and expert commentary therefore considers prucalopride a reasonable option in breastfeeding when: chronic constipation is severe; standard laxatives (bulk‑forming, osmotic, stimulant) have failed; and the benefits of continued breastfeeding outweigh theoretical risks of small drug exposure. Product information and lactation counselling resources advise weighing the mother’s clinical need against potential adverse effects on the breastfed child rather than routinely discontinuing breastfeeding.ncbi.nlm.nih+4

No specific adverse effects have been reported in breastfed infants exposed to prucalopride, but, based on its prokinetic mechanism, theoretical infant effects could include increased bowel frequency or diarrhea if exposure were higher. Current data, however, indicate that infant exposure is low and that prucalopride is compatible with breastfeeding when used with appropriate caution and surveillance.sps+2

Clinical use in breastfeeding women

For breastfeeding women with constipation, clinical guidance recommends lifestyle interventions (dietary fibre, hydration, physical activity) and safer laxatives (bulk‑forming or osmotic) as first‑line therapy, which have very low passage into breast milk and extensive experience in lactation.ncbi.nlm.nih+3
Prucalopride should be reserved for cases of chronic idiopathic constipation or functional constipation where these simpler measures and over‑the‑counter laxatives have failed, and where symptoms significantly impair maternal quality of life.medicines+4

When prucalopride is initiated in a nursing mother, standard adult dosing (usually 2 mg once daily) can be used, with dose reduction in severe renal impairment, and breastfeeding can usually continue. Infant monitoring should focus on: changes in bowel pattern (especially diarrhea), feeding behaviour, weight gain and any signs of gastrointestinal distress, though clinically significant problems are not expected at the documented low exposure.ncbi.nlm.nih+5

Clinicians should document the indication, dosing, duration, response and infant observations, and revisit therapy regularly. Prucalopride should not be used as a routine first‑line agent in breastfeeding but, given its low breast‑milk exposure, it provides a viable option for refractory constipation without unnecessary interruption of lactation.